Toxic shock syndrome primary prevention
|
Toxic shock syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Toxic shock syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Toxic shock syndrome primary prevention |
|
Risk calculators and risk factors for Toxic shock syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]
Overview
Toxic shock syndrome (TSS) can be prevented by educating people about maintaining proper hygiene. Experimental TSS vaccines may be a good choice for high risk patients.
Primary Prevention
- Increase education can help to prevent TSS. All women should be educated about the risk of TSS and the essence of frequently changing tampons.
- The spread of all types of group A streptococcal infections can be reduced by better hygiene include good hand washing, especially after coughing and sneezing and before preparing foods or eating. This can specially be helpful for prevention of non-menstrual toxic shock syndrome(TSS).[1]
- Patients with confirmed strep throat should stay at home until 24 hours after commencing antibiotic treatment.
- It is not necessary for all people exposed to someone with an invasive group A streptococcal TSS to receive antibiotic therapy to prevent infection. However, in certain circumstances, antibiotic therapy may be appropriate.
- Menstrual toxic shock syndrome can be prevented by avoiding tampons usage, especially the super absorbent variety. Risk can be reduced by changing tampons more frequently.
- All wounds specially penetrating wounds should be kept clean and watched for possible signs of infection such as pain, swelling, local drainage, and redness at the wound site.
- Experimental staphylococcal vaccines and immuno-therapies are now in clinical trials and may be introduced to the market soon.[2]
References
- ↑ "Group A Strep | Group A Streptococcus Diseases | GAS | CDC".
- ↑ Lin YC, Peterson ML (2010). "New insights into the prevention of staphylococcal infections and toxic shock syndrome". Expert Rev Clin Pharmacol. 3 (6): 753–767. doi:10.1586/ecp.10.121. PMC 3102526. PMID 21625323.